The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Treating R/R DLBCL in 2025: CAR T-cell therapy and bispecific antibodies
Nirav Niranjan Shah, MD, Medical College of Wisconsin, Milwaukee, WI, discusses the various treatment options for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). He highlights the importance of considering CAR T-cell therapy as a curative intent strategy, and notes that other options, such as bispecific antibodies, are emerging for those who do not have access to CAR-T. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
It’s a good problem to have in 2025 in that we do have more than one option for relapsed/refractory diffuse large B-cell lymphoma. However, we still have to follow the evidence. And while there are drugs up and coming, things like bispecific antibodies, they’re getting approved, hopefully in the second line, and we’re seeing really good outcomes with them, we still have to take a step back and realize that CAR T-cell therapy targeting CD19 is the true and tested therapy that went through a randomized controlled trial and showed an overall survival benefit for patients in that first relapse setting...
It’s a good problem to have in 2025 in that we do have more than one option for relapsed/refractory diffuse large B-cell lymphoma. However, we still have to follow the evidence. And while there are drugs up and coming, things like bispecific antibodies, they’re getting approved, hopefully in the second line, and we’re seeing really good outcomes with them, we still have to take a step back and realize that CAR T-cell therapy targeting CD19 is the true and tested therapy that went through a randomized controlled trial and showed an overall survival benefit for patients in that first relapse setting. Now, not every single patient will be CAR-T eligible, which is so great to have these other options. But I still think that it’s important for community doctors to look at their patients and think, you know, is CAR T-cell at least an option for them to discuss if they don’t have that opportunity available? And send them to a center that potentially does have CAR-T available, because we have five-year outcomes that show that this is a curative intent strategy. Now, for those patients who don’t have CAR T-cell therapy availability or for a multitude of reasons can’t get that treatment, the good news is we have other options. Combinations of bispecifics with chemotherapy or single agent have shown durable remissions. We don’t quite have that five-year data with bispecific antibodies to sort of say, you know, this is definitively a cure, but we do have more treatment options. And there’s more and more data being presented at this meeting as well that’s going to further advance different therapies. What I’m most excited to see in the next few years is the litany of frontline trials, R-CHOP plus X. And there’s a lot of different X combinations with R-CHOP that may really shift the entire needle in terms of how we treat frontline DLBCL, which then impacts how we treat relapsed diffuse large B-cell lymphoma. But again, good problems to have with lots of options.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
